Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown. METHODS: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors). RESULTS: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. CONCLUSIONS: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [136]
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Research works printed but not linked: 2
- 10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · DOI · Paper page
- 10.1002/(sici)1097-0215(19990621)84:3<326::aid-ijc22>3.0.co;2-k · DOI · Paper page
Cited by
Items 401–500 of 1,001
Zhao, Y., Ge, X., He, J., Cheng, Y., Wang, Z., Wang, J., & Sun, L. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1621-9 · Cited by 115
Katz, S. C., Donkor, C., Glasgow, K., Pillarisetty, V. G., Gönen, M., Espat, N. J., Klimstra, D. S., D'Angelica, M. I., Allen, P. J., Jarnagin, W. R., et al. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00231.x · Cited by 100
Understanding high endothelial venules: Lessons for cancer immunology
Ager, A., & May, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008791 · Cited by 99
Biomaterial‐Based In Situ Cancer Vaccines
Yang, B., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202210452 · Cited by 105
Sabbagh, C., Chatelain, D., Trouillet, N., et al. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-2934-3 · Cited by 99
“These outcomes have to be weighed against the large number of literature reports of a correlation between perineural invasion and survival [14, 17].”
BackgroundInfluentialWu, C., Wang, S., Wang, F., Chen, Q., Peng, S., Zhang, Y., Qian, J., Jin, J., & Xu, H. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04011.x · Cited by 106
Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer
Santhanam, S., Alvarado, D. M., & Ciorba, M. A. (2015) · Translational research · doi:10.1016/j.trsl.2015.07.003 · Cited by 105
Yoon, H. H., Orrock, J. M., Foster, N. R., Sargent, D. J., Smyrk, T. C., & Sinicrope, F. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042274 · Cited by 98
“Studies in patients with colorectal cancer (CRC) suggest that the density of tumor infiltrating lymphocytes (TILs) strongly influences clinical outcome [1,2,3].”
BackgroundInfluentialPoulet, F. M., Wolf, J. J., Herzyk, D. J., & DeGeorge, J. J. (2016) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21176 · Cited by 100
“The mechanism by which PD-1 down-modulates T-cell responses is similar to that of CTLA-4 because both molecules regulate an overlapping set of signaling proteins (Parry et al., 2005; Francisco et al., 2010).”
BackgroundSurvival after a cancer diagnosis among solid organ transplant recipients in the United States
D’Arcy, M. E., Coghill, A. E., Lynch, C. F., Koch, L., Li, J., Pawlish, K. S., Morris, C. R., Rao, C., & Engels, E. A. (2019) · Cancer · doi:10.1002/cncr.31782 · Cited by 101
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
“For example, it is described in colorectal cancer that the presence of many CD8+ T lymphocytes is a good prognosis factor [13].”
BackgroundImmune cells in colorectal cancer: prognostic relevance and therapeutic strategies
Atreya, I., & Neurath, M. F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.561 · Cited by 98
Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI
Deschoolmeester, V., Baay, M. F. D., Lardon, F., Pauwels, P., & Peeters, M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0068-5 · Cited by 116
“immune system may be a favorable prognostic sign [10].”
BackgroundInfluentialChapter 5 Expression of Chemokines and Chemokine Receptors in Human Colon Cancer
Erreni, M., Bianchi, P. P., Laghi, L., Mirolo, M., Fabbri, M., Locati, M., Mantovani, A., & Allavena, P. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)05205-7 · Cited by 101
Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
Fakih, M., Ouyang, C., Wang, C., Tu, T. Y., Gozo, M. C., Cho, M., Sy, M., Longmate, J. A., & Lee, P. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127046 · Cited by 84
Characterization of an adaptive immune response in microsatellite-instable colorectal cancer
Boissière‐Michot, F., Lazennec, G., Frugier, H., Jarlier, M., Roca, L., Duffour, J., Paty, E. D., Laune, D., Blanchard, F., Pessot, F. L., et al. (2014) · OncoImmunology · doi:10.4161/onci.29256 · Cited by 103
“signet ring cell carcinoma Yes no 4 (4) 106 (96) 2 (3) 60 (97) 2 (4) 46 (96) 1.”
Steele, K. E., Tan, T. H., Korn, R., Dacosta, K., Brown, C., Kuziora, M., Zimmermann, J., Laffin, B., Widmaier, M., Rognoni, L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0326-x · Cited by 97
“The original immunoscore itself was used to quantify CD8+ TILs in the TC and IM of colorectal cancer, but only in a few selected regions of each patient sample [29].”
BackgroundMethodInhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Borcoman, É., Rochère, P. D. L., Richer, W., Vacher, S., Chemlali, W., Krucker, C., Sirab, N., Radvanyi, F., Allory, Y., Pignot, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581556 · Cited by 97
“Tumors with a T-cell-inflamed microenvironment, also referred to as “hot tumors”, are characterized by a high CD8 T cell infiltrate, the expression of chemokines involved in T-cell recruitment,(8) and a type-I interferon (IFN) signature, and are associated with improved patient survival and better responses to immunot…”
BackgroundSelf-citationZaravinos, A., Roufas, C., Nagara, M., de Lucas, B., Oblovatskaya, M., Efstathiades, C., Dimopoulos, C., & Ayiomamitis, G. D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1372-z · Cited by 103
Tiberti, S., Catozzi, C., Croci, O., Ballerini, M., Cagnina, D., Soriani, C., Scirgolea, C., Gong, Z., He, J.-T., Macandog, A. D. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34467-3 · Cited by 106
“The contact-mediated interaction with neutrophils (5) pushes effector memoryCD8+ T cells (TEM) to producehigh levels of GranzymeK (GZMK) (6),which in turn remodels the tumormicroenvironment (TME) fostering EMT (7).”
BackgroundInfluentialBachireddy, P., Hainz, U., Rooney, M. S., Pozdnyakova, O., Aldridge, J., Zhang, W., Liao, X., Hodi, F. S., O'Connell, K. E., Haining, W. N., et al. (2013) · Blood · doi:10.1182/blood-2013-08-523001 · Cited by 103
Paulson, K. G., Iyer, J. G., Simonson, W. T., Blom, A., Thibodeau, R. M., Schmidt, M. N., Pietromonaco, S., Sokil, M., Warton, E. M., Asgari, M. M., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpikdzm39crpnc · Cited by 105
γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion
Presti, E. L., Pizzolato, G., Corsale, A. M., Caccamo, N., Sireci, G., Dieli, F., & Meraviglia, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01395 · Cited by 103
“How many mechanisms do regulatory T cells need? Eur J Immunol (2008) 38(4):908–11.”
BackgroundInfluentialPrognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia
González, A. P., Contesti, J., Huergo-Zapico, L., López‐Soto, A., Fernández-Guizán, A., Acebes‐Huerta, A., González‐Huerta, A. J., González, E., Fernández-Álvarez, C., & Gonzalez, S. R. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.503820 · Cited by 107
Cytomegalovirus-Induced γδ T Cells Associate with Reduced Cancer Risk after Kidney Transplantation
Couzi, L., Vaillant, Y. L., Jamai, A., Pitard, V., Lassalle, R., Martin, K., Garrigue, I., Hawchar, O., Siberchicot, F., Moore, N. D., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101072 · Cited by 113
An immunologic portrait of cancer
Ascierto, M. L., Giorgi, V. D., Liu, Q., Bedognetti, D., Spivey, T. L., Murtas, D., Uccellini, L., Ayotte, B. D., Stroncek, D. F., Chouchane, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-146 · Cited by 95
“[40-44], colon [23,44-53], breast [54-56], hepatocellular [44], prostatic [55-60], pancreatic [44,61], pulmonary”
BackgroundMutational profiling of colorectal cancers with microsatellite instability
Lin, E. I., Tseng, L.-H., Gocke, C. D., Reil, S., Le, D. T., Azad, N. S., & Eshleman, J. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5997 · Cited by 95
“In retrospect, this may explain the seminal observation of the profound lymphocyte infiltration [18] and better outcomes in CRCs with MSI [20, 46, 7].”
BackgroundLe, N. H., Franken, P., & Fodde, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604401 · Cited by 116
Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy
Ge, L., Hoa, N. T., Wilson, Z., Arismendi-Morillo, G., Kong, X., Tajhya, R. B., Beeton, C., & Jadus, M. R. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.06.040 · Cited by 107
“Human CTLs were elicited by two different gBK peptides and could kill human HLA-A2+ glioma cells such as U251, LN-18, T98G and U87, but failed to kill HLA-A2-negative cells such as D54 (HLA-A01/A03) or LNZ-308 (HLA-A24).”
BackgroundInfluentialNew Strategies for the Treatment of Solid Tumors with CAR-T Cells
Zhang, H., Ye, Z., Yuan, Z.-G., Luo, Z.-Q., Jin, H., & Qian, Q. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14405 · Cited by 109
“The presence of high number of tumor-infiltrating lymphocytes (TIL) and extensive infiltration have been found as major indicators of favorable patient prognosis and positive therapeutic responses in treating several solid tumors [43], including colorectal cancer [44], lung cancer [45], and ovarian carcinomas [46, 47].”
BackgroundThe Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old Acquaintances
Arias, M. A., Martínez‐Lostao, L., Santiago, L., Ferrández, Á., Granville, D. J., & Pardo, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.001 · Cited by 97
The clinical utility of the local inflammatory response in colorectal cancer
Richards, C. H., Roxburgh, C. S. D., Powell, A. G. M. T., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.008 · Cited by 102
“In addition, many studies have relied on tissue microarrays (TMA’s) [22–24] that, given the heterogenous patterns of inflammatory cell infiltration observed in the present study, may not be representative of full sections.”
BackgroundResultOsada, T., Patel, S. P., Hammond, S. A., Osada, K., Morse, M. A., & Lyerly, H. K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1671-y · Cited by 101
“The T cell response to colon and pancreatic cancers is associated with improved clinical outcome [1, 2].”
BackgroundDroeser, R. A., Zlobec, I., Kilic, E., Güth, U., Heberer, M., Spagnoli, G. C., Oertli, D., & Tapia, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-134 · Cited by 108
“Indeed, tumor infiltration by CD8 Tcells has been shown to represent an important prognostic factor in melanoma [7], and, more recently, in colorectal cancers [2,33].”
BackgroundPrognostic significance of CD45RO+ memory T cells in renal cell carcinoma
Hotta, K., Sho, M., Fujimoto, K., Shimada, K., Yamato, I., Anai, S., Konishi, N., Hirao, Y., Nonomura, K., & Nakajima, Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.368 · Cited by 92
“In colorectal cancer, high density of CD45ROþ cells within the tumour was associated with decreased invasiveness, lower stage, and prolonged survival (Pages et al, 2005, 2009; Galon et al, 2006).”
BackgroundOral Squamous Cell Carcinoma: Clinicopathological Features in Patients with and without Recurrence
Camisasca, D. R., SILAMI, M. A. N. C., Honorato, J., et al. (2011) · ORL · doi:10.1159/000328340 · Cited by 92
Should Total Number of Lymph Nodes be Used as a Quality of Care Measure for Stage III Colon Cancer?
Wang, J., Kulaylat, M. N., Rockette, H. E., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e318197f2c8 · Cited by 91
“Also, more lymph nodes are identified in patients with cancer of the proximal colon or with more advanced cancer.(40) Furthermore, there is no convincing physiological evidence to support the linkage between the TNODS and outcome of colon cancer.”
BackgroundImmune infiltrates as predictive markers of survival in pancreatic cancer patients
Protti, M. P., & De Monte, L. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00210 · Cited by 91
“Large-scale studies have then revealed the prognostic and predictive impact of immune infiltrates (Pages et al., 2005; Galon et al., 2006; Denkert et al., 2010) and international efforts have been put together to standardize predictive immune scores for prognosis in several tumor histotypes (Galon…”
BackgroundAttig, S., Hennenlotter, J., Pawelec, G., Klein, G., Koch, S. D., Pircher, H., Feyerabend, S., Wernet, D., Stenzl, A., Rammensee, H.-G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0852 · Cited by 91
“Effector memory T cells have been associated with vaccine protection, and importantly, with the absence of metastatic invasion in colon carcinoma (22, 42).”
BackgroundTumor dormancy and immunoescape
QUESNEL, B. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01163.x · Cited by 90
“Another important clinical observation is that in colon cancer, prognosis may depend on immune infiltration of early metastases, suggesting that a kind of equilibrium may occur (12, 13).”
BackgroundNathan, H., Shore, A. D., Anders, R. A., Wick, E. C., Gearhart, S. L., & Pawlik, T. M. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1410-9 · Cited by 91
Polyfunctional response by Imm TAC ( IMC gp100) redirected CD 8 + and CD 4 + T cells
Boudousquié, C., Bossi, G., Hurst, J. M., Rygiel, K. A., Jakobsen, B. K., & Hassan, N. J. (2017) · Immunology · doi:10.1111/imm.12779 · Cited by 97
Søreide, K., Nedrebø, B. S., Knapp, J.-C., Glomsaker, T. B., Søreide, J. A., & Kørner, H. (2008) · Surgical Oncology · doi:10.1016/j.suronc.2008.06.006 · Cited by 95
“Although not analysed for MSI, the recent findings of the importance of an activated immune system within CRC (and associated improved survival) suggest a link between genetics, inflammatory response and outcome [96,97].”
BackgroundT-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management
Abramson, J. S. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-384 · Cited by 94
“Infiltrating T lymphocytes appear to confer prognostic benefit in several solid tumors, including colorectal cancer [ 41 ], melanoma [42], and ovarian carcinoma [43].”
Colon cancer and the immune system: The role of tumor invading T cells
Waldner, M. J., Schimanski, C.-C., & Neurath, M.-F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i45.7233 · Cited by 111
“Another study using 959 specimens of resected colorectal cancer analyzed the correlation between tumor metastasis and T cell activation [ 31 ]”
MethodYang, Y., Attwood, K., Bshara, W., Mohler, J. L., Guru, K., Xu, B., Kalinski, P., & Chatta, G. (2021) · The Prostate · doi:10.1002/pros.24068 · Cited by 88
Søreide, K., Nedrebø, B. S., Søreide, J. A., et al. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0255-4 · Cited by 88
“One study demonstrated that the presence of large numbers of immune cells in colorectal cancers is associated with the absence of metastatic invasion, a less advanced pathologic stage, and increased survival [38].”
BackgroundBispecific antibodies engage T cells for antitumor immunotherapy
Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C.-T., & Sampson, J. H. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.572874 · Cited by 91
“Indeed, high densities of CD8 effector memory T cells have been isolated from tumor parenchyma in patients with colon cancer [18,19] and non-Hodgkin’s lymphoma (NHL) [20].”
BackgroundLohneis, P., Sinn, M., Bischoff, S., Jühling, A., Pelzer, U., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Oettle, H., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.016 · Cited by 95
“Studies on large cohorts of breast cancer [3,4] or colon carcinoma [5,6] have shed light on the prognostic and predictive impacts of tumour-infiltrating T lymphocytes.”
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
Choi, Y. W., Kim, Y. H., Oh, S. Y., Suh, K. W., Kim, Y., Lee, G., Yoon, J. E., Park, S. S., Lee, Y., Park, Y. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202002497 · Cited by 105
Extracellular vesicles as antigen carriers for novel vaccination avenues
Mehanny, M., Lehr, C.-M., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.016 · Cited by 88
Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis
Schatton, T., Scolyer, R. A., Thompson, J. F., & Mihm, M. C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_16 · Cited by 106
Kallert, S. M., Darbre, S., Bonilla, W. V., Kreutzfeldt, M., Page, N., Müller, P., Kreuzaler, M., Lu, M., Favre, S., Kreppel, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15327 · Cited by 88
Yoon, H. H., Shi, Q., Heying, E. N., Muranyi, A., Bredno, J., Ough, F., Djalilvand, A., Clements, J., Bowermaster, R., Liu, W.-W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1984 · Cited by 87
“First, CD3þ and/or CD8þ TILs appear to be prognostic across tumor stages and treatments (11, 20).”
BackgroundZhu, Z., Chen, H., Yu, W., Fu, X., Xiang, J., Li, H., Zhang, Y., Sun, M., Qiao, W., Zhao, W., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3665-y · Cited by 86
The Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 96
“Immunohistochemistry of human tumors revealed DC infiltrates with clinical relevance Although T-cell infiltrates detected within primary tumors (at least in colorectal, ovarian, melanoma patients) can have a dramatic impact on patients’ survival (Zhang et al., 2003; Ladanyi et al., 2004; Pages et al., 2005; Galon et a…”
BackgroundJinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
Tsukamoto, H., Nishikata, R., Senju, S., & Nishimura, Y. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0030 · Cited by 86
Shen, N., Wu, J., Yang, C., Yu, H., Yang, S., Li, T., Chen, J., Tang, Z., & Chen, X. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03214 · Cited by 85
Ogino, S., Nosho, K., Irahara, N., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.578 · Cited by 85
Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis?
Whiteside, T. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00107 · Cited by 87
“Subsequently, Fridman’s group has demonstrated by immunostaining of hundreds of CRC specimens that a strong local immune reaction, including CD3+, CD8+, and memory CD45RO+ T cells, correlates with a favorable prognosis regardless of the local extent of the tumor or the regional lymph node involvement (Pages et al., 20…”
BackgroundResultChen, L., Zheng, X. W., Shen, Y., Zhu, Y., Li, Q., Chen, J., Xia, R., Zhou, S.-M., Wu, C., Zhang, X., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1358-6 · Cited by 88
Richards, C. H., Flegg, K. M., Roxburgh, C. S. D., Going, J. J., Mohammed, Z., Horgan, P. G., & McMillan, D. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.211 · Cited by 86
“However, despite extensive investigation over a 40-year period, a reliable measure of the local inflammatory cell infiltrate has yet to be incorporated into clinical practice (Jass et al, 1987; Pagès et al, 2005; Forssell et al, 2007).”
BackgroundPlasmacytoid dendritic cells and cancer
Vermi, W., Soncini, M., Melocchi, L., Sozzani, S., & Facchetti, F. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411190 · Cited by 91
“[41, 42], supporting the notion that monitoring the local immune response to cancer might represent an extraordinary tool to predict patient outcome and likely, response to immunotherapy strategies.”
BackgroundJiang, B., Zhang, T., Liu, F., Sun, Z., Shi, H., Hua, D., & Yang, C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9035 · Cited by 87
“T cells play a central role in IBD and cancer growth and progression [11, 12] because they help B cells produce antibodies, secrete cytokines and chemokines, and kill virus-infected cells and cancer cells.”
BackgroundFOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 90
Induction of Protective Antitumor Immunity through Attenuation of ERAAP Function
James, E., Bailey, I., Sugiyarto, G., & Elliott, T. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300220 · Cited by 82
“There is growing evidence for the importance of tumor-infiltrating lymphocytes (including CTL) in controlling the progression of tumors, including colorectal cancer (30, 31).”
BackgroundToh, J. W. T., SOUZA, P. D., Lim, S. H.-S., Singh, P., Chua, W. M., Ng, W. L., & Spring, K. J. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.007 · Cited by 91
Eugène, J., Jouand, N., Ducoin, K., Dansette, D., Oger, R., Deleine, C., Leveque, E., Meurette, G., Podevin, J., Matysiak‐Budnik, T., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0322-9 · Cited by 88
Tumour immunotherapy: lessons from predator–prey theory
Hamilton, P. T., Anholt, B. R., & Nelson, B. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00719-y · Cited by 90
The number of analyzed lymph nodes – a prognostic factor in colorectal cancer
Edler, D., Öhrling, K., Hallström, M., et al. (2007) · Acta Oncologica · doi:10.1080/02841860701203537 · Cited by 81
“have found that the immune response within the tumours was associated with a less advanced pathological stage and prolonged survival [16].”
BackgroundHalama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., Doeberitz, M. V. K., Schirmacher, P., Weitz, J., Grabe, N., & Jäger, D. (2009) · PubMed · Cited by 93
Wang, Y., Lin, H.-C., Huang, M., Shao, Q., Wang, Z.-Q., Wang, F.-H., Yuan, Y., Li, B., Wang, D., Ding, P.-R., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2094-8 · Cited by 84
The dendritic cell–tumor cross-talk in cancer
Ma, Y., Aymeric, L., Locher, C., Kroemer, G., & Zitvogel, L. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.09.008 · Cited by 83
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Hu, G., & Wang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-11122-2 · Cited by 88
Adaptive NK cell reconstitution is associated with better clinical outcomes
Cichocki, F. M., Taras, E., Chiuppesi, F., Wagner, J. E., Blazar, B. R., Brunstein, C. G., Luo, X., Diamond, D. J., Cooley, S., Weisdorf, D. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125553 · Cited by 80
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 97
“The presence of specific immune cells within the tumor tissue, such as increased densities of T cell infiltrates with a high proportion of CD8+ T and demonstrated that immune reactivity at the tumor site influences clinical outcome [92].”
BackgroundAn update on colorectal cancer microenvironment, epigenetic and immunotherapy
Jin, K., Ren, C., Liu, Y., Lan, H., & Wang, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107041 · Cited by 90
NF-κB in Cancer Immunity: Friend or Foe?
Lalle, G., Twardowski, J., & Grinberg‐Bleyer, Y. (2021) · Cells · doi:10.3390/cells10020355 · Cited by 87
Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation
Couzi, L., Pitard, V., Moreau, J., Merville, P., & Déchanet‐Merville, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00003 · Cited by 92
Williams, D. S., Mouradov, D., Jorissen, R. N., Newman, M. R., Amini, E., Nickless, D. K., Teague, J. A., Fang, C. G., Palmieri, M., Parsons, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315664 · Cited by 79
Miyan, M., Schmidt-Mende, J., Kiessling, R. W., Poschke, I. C., & de Boniface, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0983-9 · Cited by 92
“The immunoscore developed for colorectal cancer predicts relapses among early-stage tumors more accurately than classical TNM staging and consequentially bears therapeutic implications; patients at high risk could potentially benefit from adjuvant treatment not normally given in early-stage disease [19, 20].”
Qin, J., Kunda, N. M., Qiao, G., Calata, J. F., Pardiwala, K., Prabhakar, B. S., & Maker, A. V. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.473 · Cited by 82
Tanis, E., Julié, C., Emile, J., Mauer, M. E. L., Nordlinger, B., Aust, D. E., Roth, A. D., Lutz, M. P., Gruenberger, T., Wrba, F., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.014 · Cited by 84
“Several studies in primary colorectal cancer have shown that T-cell responses (CD3 and CD8) are associated with prolonged DFS and OS [30,31].”
BackgroundDufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., Ridder, M. D., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3682 · Cited by 89
Riddell, J. R., Maier, P. G., Sass, S. N., Moser, M. T., Foster, B. A., & Gollnick, S. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050394 · Cited by 86
“The VEGF promoter contains elements for specific protein 1 (Sp1), HIF-1, NF-kB and STAT-3 (Figure 2A) [30].”
BackgroundTumor microenvironment and lymphocyte infiltration
Rahir, G., & Moser, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1253-1 · Cited by 87
Weiss, G. R., Grosh, W. W., Chianese‐Bullock, K. A., Zhao, Y., Liu, H., Slingluff, C. L., Marincola, F. M., & Wang, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1650 · Cited by 79
“Similarly, a coordinated cytotoxic Th1 immune phenotype expressing the transcription factor T-box protein 21 (T-bet), interferon regulatory factor 1 (IRF-1), and IFN-g is associatedwith goodprognosis in colorectal cancer (10, 23).”
BackgroundInfluentialTrial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 86
Self-citationBiomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 81
Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances
Hassan, H. A. F. M., Diebold, S. S., Smyth, L. A., Walters, A. A., Lombardi, G., & Al‐Jamal, K. T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.017 · Cited by 85
The Immune Microenvironment: A Major Player in Human Cancers
Fridman, W. H., Remark, R., Goc, J., Giraldo, N. A., Becht, E., Hammond, S. A., Damotte, D., Dieu-Nosjean, M.-C., & Sautès-Fridman, C. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000362332 · Cited by 77
Self-citationBento, D. F. C., Jones, E., Junaid, S., Tull, J., Williams, G. T., Godkin, A. J., Ager, A., & Gallimore, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974374 · Cited by 77
Buhrmann, C., Shayan, P., Banik, K., Kunnumakkara, A. B., Kubatka, P., Koklesová, L., & Shakibaei, M. (2020) · Biomedicines · doi:10.3390/biomedicines8080236 · Cited by 80
“It is well documented that the TME is infiltrated by a wide range of immune cell populations [69], and recent data suggest that immune cell infiltrates may also affect prognosis in CRC [70].”
BackgroundSuzuki, K., Kadota, K., Sima, C. S., Sadelain, M., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1073-8 · Cited by 76
“In ovarian and colorectal cancers, intra-tumoral inflammatory cells have been shown to be prognostic [1, 2], while in non-small cell lung cancer and more recently breast cancer, presence of inflammatory cells in the stroma has shown prognostic significance [3, 16, 19].”
BackgroundPaschos, K. A., Majeed, A. W., & Bird, N. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3719 · Cited by 89
Dendritic Cell-Based Therapeutic Cancer Vaccines: What We Have and What We Need
Kaliński, P., Urban, J. A., Narang, R., Berk, E., Wieckowski, E., & Muthuswamy, R. (2009) · Future Oncology · doi:10.2217/fon.09.6 · Cited by 88
“The possibility that improved tumor homing may translate into better outcomes of active immunotherapies is supported by the observations that the level of T -cell infiltration is a strong independent prognostic marker of the survival of cancer patients with melanoma [136] and colorectal cancer [137–139].”
BackgroundGM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer
Nebiker, C. A., Han, J., Eppenberger‐Castori, S., Iezzi, G., Hirt, C., Amicarella, F., Cremonesi, E., Huber, X., Padovan, E., Angrisani, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2774 · Cited by 78
“Cytokine and chemokine gene expressionhas been extensively investigated in colorectal cancer tissues (9, 45).”
BackgroundGene-expression profiling in vaccine therapy and immunotherapy for cancer
Bedognetti, D., Wang, E., Sertoli, M. R., & Marincola, F. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.55 · Cited by 78
Khoury, T., Nagrale, V., Opyrchal, M., Peng, X., Wang, D., & Yao, S. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000466 · Cited by 77
“patients for 1 of 3 reasons: (1) patients (n=6) had their disease before mid-2005 when trastuzumab was first implemented in the neoadjuvant setting; (2) patient (n=1) was on a clinical trial; or (3) patients (n=2) deemed not tolerant to this agent.”
Metadata
- Authors
- Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Galon, J.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Graz University of Technology (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-22
- Volume
- 353
- Issue
- 25
- Pages
- 2654-2666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096151993
- Semantic Scholar
- 608c79dfb95b1632f3cda7f427350880ee435e8a
- Cited by
- 2,135
- References
- 32
- Citations by year
- 2026: 27 · 2025: 57 · 2024: 66 · 2023: 118 · 2022: 117 · 2021: 141 · 2020: 130 · 2019: 123 · 2018: 123 · 2017: 136 · 2016: 135 · 2015: 145 · 2014: 115 · 2013: 135 · 2012: 108
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- colorectal cancer, effector memory T cells, tumor-infiltrating lymphocytes, CD8+ T cells, CD45RO+ memory T cells, T-cell markers, lymphatic invasion, perineural invasion, interferon-gamma, granzyme B, granulysin, IRF1, disease-free survival, overall survival, antitumor immunity
- MeSH terms
- Analysis of Variance, Embolism, Flow Cytometry, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger, T-Lymphocytes, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Survival Analysis, Polymerase Chain Reaction, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Microarray Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.